CD8A and acute myeloid leukemia: Previous studies have shown that the increased proportion of CD8+ T cells in the blood of AML patients receiving anthracycline consolidation therapy contributes to the efficacy of immunotherapy with histamine dihydrochloride (HDC) and IL-2, and improves the survival rate of patients, which is due to the increased responsiveness of immunotherapy due to ICD generated by consolidation therapy [28].